Belinostat (PXD101) is a novel hydroxamate-type inhibitor of histone
deacetylase (HDAC) activity. Belinostat inhibits HDAC activity in HeLa
cell extracts with an IC50 of 27 nM. PXD101 is cytotoxic in vitro in a
number of tumor cell lines with IC50s in the range 0.2-3.4 uM as
determined by a clonogenic assay and induces apoptosis.
Steele NL, Plumb JA, Vidal L, et al. Clin Cancer Res. 2008 Feb 1;14(3):
804-10. Buckley MT, Yoon J, Yee H, et al.J Transl Med. 2007 Oct 12;5:49.